Xencor's stock drops 65%, hitting all-time lows. Focus shifts to autoimmune research, but no near-term catalysts. Read why ...

Xencor (XNCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

American Century Companies Inc. raised its stake in shares of Xencor, Inc. (NASDAQ:XNCR – Free Report) by 11.1% during the ...

Xencor (XNCR) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the ...

This irresponsible form of political theater is on display regarding the necessary and critical role capital investing plays ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Xencor, Inc. (NASDAQ:XNCR), a biotechnology company specializing in protein engineering and T cell engager (TCE) technologies, stands at a critical juncture in its development. With a diverse ...

Xencor, Inc. (NASDAQ:XNCR), a biotechnology company specializing in protein engineering and T cell engager (TCE) technologies, stands at a critical juncture in its development. With a diverse pipeline ...